ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Midphase failure of Novartis’ NASH drug crushes Conatus
fiercebiotech
December 29, 2018A phase 2b trial of Conatus Pharmaceuticals’ emricasan has?missed?its primary endpoint. The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months.....
Pharma Sources Insight January 2025
